Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (ALLIANCE).


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Patel, JN; Jiang, C; Hertz, DL; Mulkey, F; Friedman, PN; Halabi, S; Ratain, MJ; Morris, MJ; Small, EJ; Owzar, K; Kelly, WK; McLeod, HL

Published Date

  • May 20, 2014

Published In

Volume / Issue

  • 32 / 15_suppl

Start / End Page

  • e16061 - e16061

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2014.32.15_suppl.e16061